RecruitingACTRN12613000594729

Study to determine levels of Fibroblast Growth Factor 23 and other associated markers of bone turnover in men with various iron store states of iron overload, iron deficiency and normal iron stores.

Study comparing differences in fibroblast growth factor 23 and other markers of bone turnover in men with various iron store states of iron overload, iron deficiency and normal iron stores.


Sponsor

Associate Professor Emily Hibbert

Enrollment

140 participants

Start Date

Aug 8, 2013

Study Type

Observational

Conditions

Summary

This study is a cross sectional case control study which will determine levels of FGF23, a phosphate regulatory protein produced by osteocytes in men with iron overload, using haemochromatosis as a model of iron overload, in men with iron deficiency and in men with normal iron stores. Associated markers of bone metabolism will be measured in blood and urine and bone densitometry and body composition studies will be performed by Dual X-ray absorptiometry.


Eligibility

Sex: MalesMin Age: 35 Yearss

Inclusion Criteria4

  • The study population will comprise males of age 35 years or greater who meet one of the following criteria:
  • iron overload due to haemochromatosis with ferritin > 300microg/l, the upper limit of the reference range or
  • normal iron studies
  • iron deficiency with ferritin < 30 microg/l ie. below the lower limit of the reference range

Exclusion Criteria6

  • Intercurrent proven evidence of cancer – as this will affect ferritin levels and interpretation and may alter FGF 23
  • Active infection- will affect ferritin levels and interpretation and may alter FGF 23
  • Chronic kidney disease with eGFR< 50 - as eGFR drops, FGF23 levels rise rapidly
  • Current glucocorticoid use,
  • Hypercalcaemia
  • Vitamin D deficiency with 25OH vitamin D level < 25 nmol/l

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Not applicable- observational study Levels of FGF23, associated blood and urine markers of bone metabolism and bone mass are being studied. The duration of observation in each participant is at a sin

Not applicable- observational study Levels of FGF23, associated blood and urine markers of bone metabolism and bone mass are being studied. The duration of observation in each participant is at a single time point.


Locations(2)

Nepean Hospital - Kingswood

NSW, Australia

Blue Mountains District ANZAC Memorial Hospital - Katoomba

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12613000594729


Related Trials